Equities research analysts forecast that Cardiome Pharma Corp (NASDAQ:CRME) (TSE:COM) will post earnings per share (EPS) of ($0.19) for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Cardiome Pharma’s earnings, with estimates ranging from ($0.22) to ($0.17). Cardiome Pharma posted earnings per share of ($0.18) in the same quarter last year, which would suggest a negative year over year growth rate of 5.6%. The company is expected to report its next earnings results on Tuesday, March 6th.

According to Zacks, analysts expect that Cardiome Pharma will report full year earnings of ($0.84) per share for the current fiscal year, with EPS estimates ranging from ($0.88) to ($0.81). For the next year, analysts anticipate that the business will post earnings of ($0.72) per share, with EPS estimates ranging from ($0.89) to ($0.59). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that follow Cardiome Pharma.

Cardiome Pharma (NASDAQ:CRME) (TSE:COM) last announced its quarterly earnings data on Tuesday, November 14th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.04). The firm had revenue of $6.02 million during the quarter, compared to the consensus estimate of $7.42 million. Cardiome Pharma had a negative net margin of 112.91% and a negative return on equity of 94.68%. The business’s revenue was up 14.9% compared to the same quarter last year. During the same period last year, the business earned ($0.19) earnings per share.

A number of research analysts recently issued reports on CRME shares. Zacks Investment Research cut shares of Cardiome Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, November 14th. Canaccord Genuity set a $5.00 price objective on shares of Cardiome Pharma and gave the company a “buy” rating in a research note on Wednesday, November 15th. Mackie upgraded shares of Cardiome Pharma to a “buy” rating in a research report on Friday, December 15th. Finally, HC Wainwright restated a “buy” rating and issued a $9.50 target price on shares of Cardiome Pharma in a research report on Wednesday, November 22nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. Cardiome Pharma presently has an average rating of “Hold” and an average target price of $5.50.

Shares of Cardiome Pharma (NASDAQ CRME) traded up $0.03 during trading hours on Wednesday, reaching $1.57. 51,442 shares of the company were exchanged, compared to its average volume of 93,501. The company has a market capitalization of $54.30, a PE ratio of -1.89 and a beta of 0.83. The company has a debt-to-equity ratio of 1.67, a current ratio of 5.52 and a quick ratio of 4.71. Cardiome Pharma has a fifty-two week low of $1.29 and a fifty-two week high of $4.84.

Large investors have recently modified their holdings of the company. JPMorgan Chase & Co. lifted its holdings in shares of Cardiome Pharma by 37.6% during the second quarter. JPMorgan Chase & Co. now owns 155,095 shares of the biopharmaceutical company’s stock worth $701,000 after purchasing an additional 42,416 shares during the period. AlphaOne Investment Services LLC lifted its holdings in Cardiome Pharma by 14.9% in the second quarter. AlphaOne Investment Services LLC now owns 632,739 shares of the biopharmaceutical company’s stock valued at $2,860,000 after buying an additional 82,027 shares during the period. Stonepine Capital Management LLC lifted its holdings in Cardiome Pharma by 79.7% in the third quarter. Stonepine Capital Management LLC now owns 2,866,785 shares of the biopharmaceutical company’s stock valued at $6,106,000 after buying an additional 1,271,236 shares during the period. Finally, Westfield Capital Management Co. LP lifted its holdings in Cardiome Pharma by 8.0% in the second quarter. Westfield Capital Management Co. LP now owns 5,286,340 shares of the biopharmaceutical company’s stock valued at $23,894,000 after buying an additional 391,392 shares during the period. Institutional investors own 52.48% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was first posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.watchlistnews.com/cardiome-pharma-corp-crme-expected-to-post-earnings-of-0-19-per-share/1801888.html.

About Cardiome Pharma

Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.

Get a free copy of the Zacks research report on Cardiome Pharma (CRME)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cardiome Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma and related companies with MarketBeat.com's FREE daily email newsletter.